BridgeBio Oncology Therapeutics (BBOT) Research & Development (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Research & Development for 3 years, with the latest figure at $39.8 million in Q1 2026.

• Quarterly Research & Development rose 92.89% year-over-year to $39.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.6 million (changed N/A YoY) and the FY2025 annual result came in at $121.2 million, up 65.78% from the prior year.
• Research & Development climbed to $39.8 million in Q1 2026 per BBOT's latest filing, from $38.1 million in the prior quarter.
• Over five years, Research & Development peaked at $39.8 million in Q1 2026 and troughed at $17.9 million in Q3 2024.
• A 3-year average of $28.5 million and a median of $27.8 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2025 and 2026: Research & Development surged 95.94% in 2025, then surged 92.89% in 2026.
• Over 3 years, Research & Development stood at $19.5 million in 2024, then soared by 94.85% to $38.1 million in 2025, then increased by 4.54% to $39.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $39.8 million, $38.1 million, and $35.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.